GSK advances in Hepatitis B cure with FDA’s fast track for bepirovirsen

Pallavi Madhiraju- February 13, 2024 0

In a significant development for the treatment of chronic hepatitis B (CHB), GSK plc (LSE/NYSE: GSK) has announced that the US Food and Drug Administration ... Read More

AstraZeneca, Ionis Pharmaceuticals get FDA approval of Wainua for ATTRv-PN

Pallavi Madhiraju- December 22, 2023 0

In a major development for hereditary transthyretin-mediated amyloidosis (ATTRv-PN or hATTR-PN) patients, the US Food and Drug Administration (FDA) has approved Wainua (eplontersen), developed by ... Read More

Ionis Pharmaceuticals begins donidalorsen phase 3 trial in hereditary angioedema

pallavi123- November 28, 2021 0

Ionis Pharmaceuticals, a US-based developer of RNA-targeted therapies, has launched the OASIS-HAE phase 3 clinical trial for donidalorsen (formerly IONIS-PKK-LRx) in patients having hereditary angioedema ... Read More

Ionis Pharmaceuticals to take full ownership of Akcea Therapeutics

pharmanewsdaily- September 1, 2020 0

Ionis Pharmaceuticals is set to take full ownership of Akcea Therapeutics by acquiring the remaining stake of around 24% in the latter for about $500 ... Read More